NASH market share

View All

World Pharma News
EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline

EU approves the use of Libtayo for cutaneous squamous cell carcinoma The National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has issued guidelines regarding the funding of Libtayo (cemiplima). Libtayo, co-developed by Sanofi and Regeneron, was granted...

Find More

NASH Emerging therapies
NASH Emerging Therapies

Earlier in our article, we discussed how mostly off-label therapies so far dominate the NASH therapeutics market. So, let us dig deeper into it and find out what can we expect in the coming years in term of NASH treatments. As we know, there is no approved therapy available for NASH, and many Doctors rely on off-la...

Find More

NASH therapies
Off-label therapies dominate NASH Market Share

NASH market share of off label therapies, it will keep on experiencing a steady growth until a standard approved therapy enters the NASH treatment market. Non-alcoholic fatty liver disease (NAFLD), is the most common group of conditions in which there is an excess fat accumulation in the liver in people who i...

Find More